公开(公告)号：US20230364055A1

公开(公告)日：2023-11-16

申请号：US18223355

申请日：2023-07-18

申请人： Chinook Therapeutics, Inc.

发明人： Philip Thomas Frohlich ,  Andrew James King ,  Chidambaram Ramachandran ,  Sarah Beth Noonberg

IPC分类号： A61K31/4025 ,  A61P13/12 ,  A61K45/06 ,  A61P7/12 ,  C07D405/04

CPC分类号： A61K31/4025 ,  A61P13/12 ,  A61K45/06 ,  A61P7/12 ,  C07D405/04 ,  A61K31/472

摘要： Provided herein are methods of improving kidney function in a subject in need thereof.

公开(公告)号：US20230129646A1

公开(公告)日：2023-04-27

申请号：US17888766

申请日：2022-08-16

申请人： Chinook Therapeutics, Inc.

发明人： Philip Thomas Frohlich ,  Andrew James King ,  Chidambaram Ramachandran ,  Sarah Beth Noonberg

IPC分类号： A61K31/4025 ,  A61P13/12 ,  A61K45/06 ,  A61P7/12 ,  C07D405/04

摘要： Provided herein are methods of improving kidney function in a subject in need thereof.

公开(公告)号：US11628153B2

公开(公告)日：2023-04-18

申请号：US16975184

申请日：2019-05-27

申请人： Kao Corporation

发明人： Naoya Kitamura

IPC分类号： A61K31/216 ,  A23L33/105 ,  A61P7/12 ,  A61P13/00 ,  A23L2/52 ,  A61K9/00 ,  A61K36/535

摘要： An agent for preventing or ameliorating nocturia, containing rosmarinic acid or a salt thereof as an active ingredient.

公开(公告)号：US11453666B2

公开(公告)日：2022-09-27

申请号：US16826046

申请日：2020-03-20

申请人： Cancer Research Technology Limited

发明人： Martin Lee Stockley ,  Ellen Catherine Macdonald ,  Pritom Shah ,  Allan Jordan ,  James Hitchin ,  Niall Hamilton

IPC分类号： A61P1/00 ,  A61P1/16 ,  A61P29/00 ,  A61P31/20 ,  A61P31/14 ,  A61P31/12 ,  A61P3/10 ,  A61P7/12 ,  A61P17/00 ,  A61P17/04 ,  A61P17/02 ,  A61P35/00 ,  A61P35/02 ,  A61P7/04 ,  A61P7/02 ,  A61P13/02 ,  A61P13/12 ,  A61P9/12 ,  A61P9/00 ,  A61P43/00 ,  A61P19/04 ,  A61K31/5025 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/404 ,  A61K31/551 ,  A61K31/55 ,  A61K31/496 ,  A61K31/4184 ,  A61K45/06 ,  C07D235/02 ,  C07D471/04 ,  A61K31/437

摘要： The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

公开(公告)号：US20220273703A1

公开(公告)日：2022-09-01

申请号：US17628695

申请日：2020-07-22

申请人： University Of Pittsburgh-Of The Commonwealth System Of Higher Education

发明人： Francisco J. Schopfer ,  Dario A. Vitturi Iglesias ,  Soma Jobbagy

IPC分类号： A61K33/14 ,  A61K45/06 ,  A61P7/12

摘要： Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.

公开(公告)号：US10316034B2

公开(公告)日：2019-06-11

申请号：US15567536

申请日：2016-04-22

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom

IPC分类号： C07D471/04 ,  A61P27/02 ,  A61P17/06 ,  A61P37/02 ,  A61P9/10 ,  A61P25/28 ,  A61P31/00 ,  A61P37/08 ,  A61P7/12 ,  A61P9/04 ,  A61P25/08 ,  A61P25/16 ,  A61P29/00 ,  A61P17/04

摘要： The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.

公开(公告)号：US20180265535A1

公开(公告)日：2018-09-20

申请号：US15756665

申请日：2016-09-02

申请人： Eloxx Pharmaceuticals Ltd.

发明人： Timor BAASOV

IPC分类号： C07H15/224 ,  C07H15/23 ,  A61P7/04 ,  A61P7/12 ,  A61P21/04

CPC分类号： C07H15/224 ,  A61P7/04 ,  A61P7/12 ,  A61P21/04 ,  C07H15/23

摘要： Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.

公开(公告)号：US10000542B2

公开(公告)日：2018-06-19

申请号：US14399087

申请日：2013-05-02

申请人： Novo Nordisk A/S

发明人： Jacob Kofoed ,  Patrick W. Garibay ,  Jesper Lau

IPC分类号： A61K38/26 ,  A61P3/10 ,  A61P7/12 ,  C07K14/605 ,  A61K38/00

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/26

摘要： The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

公开(公告)号：US09487570B2

公开(公告)日：2016-11-08

申请号：US13698819

申请日：2010-05-17

申请人： Shaojing Hu ,  Fenlai Tan ,  Yanping Wang ,  Cunbo Ma ,  Yunyan Hu ,  Hong Cao ,  Xiangdong Zhao ,  Wei Long ,  Yinxiang Wang ,  Lieming Ding

发明人： Shaojing Hu ,  Fenlai Tan ,  Yanping Wang ,  Cunbo Ma ,  Yunyan Hu ,  Hong Cao ,  Xiangdong Zhao ,  Wei Long ,  Yinxiang Wang ,  Lieming Ding

IPC分类号： A61K38/26 ,  A61P3/10 ,  A61P7/12 ,  C07K14/605 ,  A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K9/00

CPC分类号： C07K14/605 ,  A61K9/0019 ,  A61K38/00

摘要： The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

摘要翻译： 本发明涉及胰高血糖素样肽的新型类似物和可用于上调哺乳动物胰岛素表达和治疗糖尿病的组合物。 特别地，这些肽衍生物具有肽模拟接头并且提供用于治疗糖尿病和其它促胰岛素肽相关疾病，胃肠功能和与胰高血糖素水平相关的活性的长期作用。

公开(公告)号：US09381176B2

公开(公告)日：2016-07-05

申请号：US13774516

申请日：2013-02-22

申请人： Wisconsin Alumni Research Foundation

发明人： Mark Keller ,  Alan Attie ,  Michelle Kimple

IPC分类号： A61K38/00 ,  A61K8/28 ,  A61K38/26 ,  A61P5/50 ,  A61P3/08 ,  A61P3/10 ,  A61P7/12 ,  C07K14/605 ,  A61K31/18 ,  A61K31/404 ,  A61K31/4985

CPC分类号： A61K31/18 ,  A61K31/404 ,  A61K31/4985 ,  A61K38/26 ,  A61K2300/00

摘要： Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.

摘要翻译： 本文提供了增加β细胞胰岛素分泌的方法。 本文还提供的方法包括向需要增加胰岛素分泌的受试者施用包含直接或间接激活腺苷酸环化酶的化合物和减弱Gα-亚家族（GSIS）的E前列腺素3（EP3）受体拮抗剂的组合物 - 介导的腺苷酸环化酶抑制。